Abstracts tagged "Experimental Arthritis"

Abstract Number: 0947 • ACR Convergence 2024
REX-7117 Is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis
Alexandra Gardino¹, Neil Bifulco¹, Jeremy Hunt², Rishi Vaswani¹, Donglim Park², Patrick Metz², Ksenya Cohen-Katsenelson², Jeong-Ho Kim², Xia Tian², Aryan Alavi², Ajay Nirula², Daniel Treiber², Brian Hodous¹, Seong Kim³ and Paul Smith², ¹Recludix Pharma, Cambridge, MA, ²Recludix Pharma, San Diego, CA, ³Department of Microbiology and Immunology, LSU Health Shreveport, Shreveport, LA
Background/Purpose: Inhibition of JAK family signaling has translated into clinically meaningful efficacy in rheumatoid arthritis, psoriatic arthritis and other inflammatory diseases. However, small molecule JAK/TYK2…
Abstract Number: 0948 • ACR Convergence 2024
Neuronal Intestinal Dysplasia Due to Ncx Gene Deficiency Attenuates the Severity of Experimental Arthritis in Mice
Takayoshi Owada¹, Keiko Hatanaka², Ayae Tanaka², Kei Ikeda³, Hirokuni Hirata¹, Yasutsugu Fukushima¹, Kazuhiro Kurasawa² and Masafumi Arima², ¹Dokkyo Medical University Saitama Medical Center, Koshigaya, Saitama, Japan, ²Dokkyo Medical University, Mibu-machi, Shimotsuga-gun, Tochigi, Japan, ³Dokkyo Medical University, Mibu, Shimotsuga, Tochigi, Tochigi, Japan
Background/Purpose: Loss of bacterial diversity and increases of specific bacteria in the gut microbiota have been observed in inflammatory arthritis such as rheumatoid arthritis…
Abstract Number: 0949 • ACR Convergence 2024
CCN1 Is a Novel Therapeutic Target for Reducing Structural Damage in Rheumatoid Arthritis: Demonstration from 2 Preclinical Models
Manon Lesturgie-Talarek¹, Jérôme Avouac², Virginie Gonzalez³, Anne Cauvet¹, Francoise Tilotta⁴ and Yannick Allanore⁵, ¹Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, France, ²Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ³Université de Paris, Institut Cochin, INSERM U1016 CNRS UMR8104, Paris, Ile-de-France, France, ⁴UFR Odontologie, and Plateforme Imagerie du Vivant, Université Paris Cité, Montrouge, France, ⁵Université Paris Cité, Paris, France
Background/Purpose: We have previously shown that the matricellular protein CCN1, characterized by angiogenic and immunomodulatory properties, is overexpressed in endothelial cells and synovial tissue of…
Abstract Number: 2263 • ACR Convergence 2024
The Potential Use of Circulating Extracellular Vesicles for Improved Diagnosis and Therapy in Rheumatic Inflammatory/autoimmune Diseases: Proof of Concept Studies
Gilad Halpert¹, Ori Moskovitch², Linoy Israel², Eri Govrin², Boris Gilburd², Ori Segal², Adi Anaki³, Tal Caller², Daniel Yechiali², Shlomo Segev², Omer Gendelman⁴, Abdulla Watad⁵, Ruty Mehrian-Shai², Rachella Popovtzer³ and Howard Amital⁶, ¹CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, ²Sheba Medical Center, Ramat-Gan, Israel, ³Bar Ilan University, Ramat-Gan, Israel, ⁴Sheba Medical Center, Ramat Gan, Israel, ⁵Tel Hashomer Medical Center, Ramat Gan, Israel, ⁶Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel
Background/Purpose: Many patients with rheumatic conditions do not completely respond or are refractory to biological therapy. Therefore, there are unmet medical needs in the treatment…
Abstract Number: 2542 • ACR Convergence 2024
Group 2 Innate Lymphoid Cells Aggravates Development of Inflammatory Arthritis
Anders Nguyen¹, Miriam Bollmann¹, Agnieszka Lastowska², Anna-Karin Hultgård Ekwall¹, Dietmar Zaiss³, Gary Firestein⁴ and Mattias Svensson⁵, ¹University of Gothenburg, Göteborg, Sweden, ²University of Gothenburg, Goteborg, Sweden, ³University Hospital Regensburg, Regensburg, Germany, ⁴University of California, San Diego, San Diego, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Activation of fibroblast-like synoviocytes (FLS) by immune cells drives inflammation and joint damage in rheumatoid arthritis (RA). Hence, understanding factors that induce destructive behaviors…
Abstract Number: 0923 • ACR Convergence 2024
Immunization of Arthritis Prone Mice with Malondialdehyde-Acetaldehyde Modified Vimentin Induces Post-Translational Protein Modifications and Extracellular Matrix Deposition in Heart Tissues
Kimberley Sinanan¹, Wenxian Zhou², Michael Duryee¹, Nozima Aripova¹, Jill Poole¹, Carlos Hunter¹, Amy Nelson¹, Tate Johnson¹, Daniel Anderson³, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Bellevue, NE, ³University of Nebraska Medical Center, Durham, NC
Background/Purpose: Recent studies have highlighted the importance of malondialdehyde-acetaldehyde (MAA)-modified proteins and resulting immune responses in the pathogenesis of rheumatoid arthritis (RA). MAA adducts have…
Abstract Number: 0937 • ACR Convergence 2024
A Novel Quantitative Method Reveals Bone-Structural Changes During Course of Inflammatory Arthritis
Anders Nguyen¹, David McBride², Miriam Bollmann¹, Agnieszka Lastowska³ and Mattias Svensson⁴, ¹University of Gothenburg, Göteborg, Sweden, ²Calibr-Skaggs Institute for Innovative Medicines, La Jolla, CA, ³University of Gothenburg, Goteborg, Sweden, ⁴University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory disease characterized by both localized and generalized bone loss. The inhibition of Receptor Activator of Nuclear Factor…
Abstract Number: 0940 • ACR Convergence 2024
Trans-endothelial Migration of Synovial Fibroblasts Promotes Arthritis Severity Through a PKD1-mediated Feedback Loop
Jaeyeon Kim, Richard Ainsworth and Nunzio Bottini, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: The application of single cell genomic approaches to the study of rheumatoid synovium has recently enabled scientists to study the complex relationship between different…
Abstract Number: 0944 • ACR Convergence 2024
Targeting Defective Macrophages to Restore Resolution of Inflammation in Rheumatoid Arthritis -Perspectives for an Autologous Secretome Therapy
Melanie Couturier¹, Francis Bonnefoy², emilie Gaiffe³, Charline Vauchy⁴, Suzanne Behlke², ERIC TOUSSIROT⁵ and Sylvain Perruche², ¹1MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ²MED’INN’Pharma, F-25000 Besançon, France, Besançon, France, ³INSERM CIC -1431 CHU Besançon, France, Besançon, France, ⁴INSERM CIC-1431, CHU de Besançon, Besancon, France, Besançon, France, ⁵university hospital of BESANCON, besancon, France
Background/Purpose: Impaired macrophage efferocytosis, a key hallmark of failed inflammation resolution, is reported in many immune-mediated inflammatory diseases, including in Rheumatoid Arthritis (RA). Hence the…
Abstract Number: 0793 • ACR Convergence 2023
The Dual Specificity Phosphatase 6 (DUSP6) Regulates Arthritis Severity and IL10 Production
Teresina Laragione, Carolyn Harris, Natasha Rice and Percio Gulko, Icahn school of Medicine at Mount Sinai, New York, NY
Background/Purpose: We have previously identified the Huntingtin-interacting protein-1 (HIP1) as a new gene implicated in the regulation of the rheumatoid arthritis (RA) fibroblast-like synoviocyte (FLS)…
Abstract Number: 0796 • ACR Convergence 2023
Role of Group 2 Innate Lymphoid Cells in the Pathogenesis of Rheumatoid Arthritis
Anders Nguyen¹, Agnieszka Lastowska¹, Miriam Bollmann¹, Symeon Kourmoulakis¹, Charlotte E. van der Plas¹, Anna-Karin Hultgård Ekwall², Dietmar M. Zaiss³, Gary S Firestein⁴ and Mattias N.D Svensson⁵, ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ³Faculty of Medicine, Department of Immune Medicine, University of Regensburg, Regensburg, Germany, Regensburg, Germany, ⁴Department of Medicine, University of California San Diego, La Jolla, CA, ⁵University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Immune-cell mediated activation of joint-lining fibroblast-like synoviocytes (FLS) play a key role in joint inflammation and destruction during Rheumatoid arthritis (RA). Thus, identifying factors…
Abstract Number: 0797 • ACR Convergence 2023
Innate Lymphoid Cells Enhance Development of CD4+ T-cell Driven Autoimmune Arthritis
Agnieszka Lastowska¹, Charlotte E. van der Plas¹, Anders Nguyen¹, Symeon Kourmoulakis¹, Miriam Bollmann¹ and Mattias N.D Svensson², ¹Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ²University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Innate Lymphoid cells (ILCs) are innate counterparts to T-cells that, based on their functional phenotype, can be divided into three subpopulations called Group 1…
Abstract Number: 0802 • ACR Convergence 2023
Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells
Samuel Kemble¹, Christopher Mahony², Charlotte Smith², Joel Rurik³, Haig Aghajanian³, Jonathan Epstein³, Mark Coles⁴ and Adam Croft², ¹University Birmingham, Rugeley, United Kingdom, ²University of Birmingham, Birmingham, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
Abstract Number: 1020 • ACR Convergence 2021
Enhancing Endothelial Cell Barrier Function via Sphingosine -1 Phosphate Receptor 1 (S1PR1) – a Novel Treatment for Experimental Arthritis
Nathalie Burg, Ryan Malpass, Carl Blobel and Jane Salmon, Hospital for Special Surgery, New York, NY
Background/Purpose: S1PR1 signaling plays critical roles in EC barrier function and vascular health, but until now, research on S1PR1 modulation in autoimmune rheumatic disease has…
Abstract Number: 0450 • ACR Convergence 2020
In Vitro Characterization of Inflammatory Arthritis Associated with Immune Check Point Inhibition
Anne Sofie Sørensen¹, Morten Nørgaard Andersen¹, Kristian Juul-Madsen², Cæcilie Deisting Skejø¹, Henrik Schmidt¹, Thomas Vorup-Jensen¹ and Tue Wenzel Kragstrup¹, ¹Aarhus University, Aarhus, Denmark, ²Aarhus University, Aarhus, Midtjylland, Denmark
Background/Purpose: During treatment with immune checkpoint inhibitors (ICI) such as the anti-PD-1 antibody pembrolizumab, 2-4% of cancer patients develop inflammatory arthritis as an immune-related adverse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].